Three-pronged attack on kidney cancer
- Researcher: Professor Hardev Pandha
- Institution: University of Surrey, England
- Award Amount: £198,670 for 3 years from 1st April 2019
- Cancer Type: Kidney Cancer
Professor Hardev Pandha, based at the University of Surrey, England, wants to make drugs like nivolumab work for as many patients as possible. His team are investigating a new three-pronged combination therapy that they hope will ultimately improve how nivolumab works. They are using a genetically modified virus that has been designed to help the immune system target and destroy cancer cells, alongside a second drug that “starves” the cancer cells of certain nutrients. Combining these two drugs with nivolumab could make this treatment more effective for more people. All of these drugs are currently being tested in patients so, if successful, this work could be rapidly taking forward into clinical trials.
This project has been made possible thanks to a co-funding partnership with Kidney Research UK.
The Research That Is Happening Right Now
Explore current projects to see how far-reaching our research is from a global perspective.
See the difference our research projects make.